Abstract: This invention is directed to coral scaffolds seeded with precursor cells in culture in the presence of a chelator and uses thereof in inducing or enhancing bone and/or cartilage formation in a subject, and kits related thereto. This invention is also directed to use of cadherin-upregulating coral for treating cancer or inhibiting cancer progression. This invention is also directed to use of aragonite or calcite-producing species for in vivo calcium release, and its application to the treatment of skin diseases, disorders or conditions.

Abstract: A process which comprises providing a porous matrix, mixing said porous matrix with a precursor solution containing manganese and cerium ions dissolved therein, triggering the formation of a non-fluid phase which contains manganese and cerium in the interior of said porous matrix, separating said porous matrix from a liquid phase containing soluble metals, completing the formation of said non-fluid phase which contains manganese and cerium in the interior of said porous matrix, heat treating said porous matrix to convert said non-fluid phase containing manganese and cerium placed therein into a manganese oxide-cerium oxide composite, and isolating said composite from said porous matrix. The resulting composite, and its use as a catalyst, are also provided.

Abstract: A dual-mode logic gate, for selectable operation in either of static and dynamic modes, includes: a static gate which includes at least one logic input and a logic output; a mode selector, configured for outputting a turn-off signal to select static mode operation and for outputting a dynamic clock signal to select dynamic mode operation; and a switching element associated with the mode selector static gate, comprising a first input connected to a constant voltage, a second input for inputting the mode selection signal from the mode selector, and an output connected to a logic output of the static gate. The switching elements switches the logic gate operation from static to dynamic mode, by applying the appropriate signal to the switching element.

Abstract: Inhibitors of cPLA2? expression are used in the preparation of pharmaceutical compositions for the inhibition of cancer cell proliferation and for the treatment of cancer; the inhibitors are selected from cPLA2?-specific ribozymes, RNA sequences usable for RNA-interference of the cPLA2? gene, and antisense oligonucleotides directed against cPLA2?.

Abstract: The present invention is primarily directed to a mutant strain of Parietochloris incisa, characterized in comprising a substantially reduced intracellular concentration of arachidonic acid (AA) together with a substantially increased intracellular concentration of dihomo-gamma-linolenic acid 20:3?6 (DGLA).

Abstract: This invention provides a polycrystalline yttrium aluminum garnet (YAG) which is transparent in the visible and near infrared region. The invention also provides a method of manufacturing a transparent sintered YAG, which has nearly no porosity.

Abstract: An optical coherence tomography (OCT) imager comprising: a low coherence light source that provides light; a photosensor for imaging light; optics that directs a first portion of the light along a first optical path so that it is imaged on the photosensor and a second portion of the light along a second optical path so that it is reflected by material in the target to the photosensor where it is imaged to interfere with light from the first portion to form an interference pattern; and a mask through which light from at least one of the first and second portions of light passes that generates a relative phase perturbation between portions of light that passes through it.

Abstract: Antisense oligonucleotides against cPLA2 are provided, which are capable of inhibiting cPLA2 expression as well as superoxide production, especially in phagocytes. These antisense oligonucleotides are powerful agents for the treatment of inflammatory conditions, in particular arthritis, as well as in neurodegenerative diseases. The antisense oligonucleotides or compositions comprising the same may be used in methods of treatment of such diseases.

Abstract: The site-specific expression of selectins on endothelial cells of blood vessels during angiogenesis provides an opportunity to target anti-cancer drugs to the vascular endothelium to extend the range of the therapeutic effect. This invention describes an innovative drug targeting strategy for the selective delivery of the anticancer drugs to endothelial cells by means of polymer-drug conjugates modified with a carbohydrate ligand for the vascular selectins. A model chemotherapeutic drug, doxorubicin, and the E-selectin ligand, sLex, are attached to a biocompatible polymer (HPMA). The selective binding, cellular uptake, intracellular fate, and cell cytotoxicity of the polymer-bound drug are investigated in human endothelial cells.

Abstract: The invention provides virus-like particles for treatment of viral infections based on the virus causing the infection. The virus-like particles comprise the virus recombinant proteins that form a capsid, recombinant virus membrane proteins attached to the capsid and vRNA packaged within said capsid. The vRNA is generated from a DNA sequence encoding a polypeptide capable of specifically binding to a constant region of a nonstructural protein of the virus that is essential for propagation of the virus.

Abstract: The present invention provides a protein, specifically Parietochloris incisa acetohydroxyacid synthase, and methods for producing branched-chain amino acid in a cell. The present invention further provides polypeptides and polynucleotides useful for conferring herbicide resistance in a cell or an organism. In particular, the present invention discloses a mutated acetohydroxyacid synthase which is resistant to herbicides.

Abstract: There is provided a composite membrane, which may include an electronically conductive asymmetric porous support and an electro-polymerized selective layer. There is also provided a composite membrane for water application(s), which may include an electronically conductive porous support and an electro-polymerized selective layer. Moreover, there is provided a composite membrane for gas application(s), which may include an electronically conductive asymmetric porous support and an electro-polymerized selective layer. There is also provided a membrane system which may include at least one composite membrane which may include an electronically conductive asymmetric porous support and an electro-polymerized selective layer. In addition there is provided a method for the preparation of a composite membrane.

Abstract: An isolated protein which is at least partially encoded by a polynucleotide sequence encoding a novel elongase is provided together with a composition which includes the isolated protein. A transgenic plant or a transgenic seed transformed by a polynucleotide encoding a protein which is at least partially encoded by a novel elongase is also provided. The invention also includes a process for making a very long-chain polyunsaturated fatty acid in a transformed cell or plant expressing the isolated protein which is at least partially encoded by a polynucleotide sequence encoding a novel elongase.

Abstract: The present invention relates in general to the field of tissue engineering and more specifically to amphiphilic peptides and peptide matrices thereof useful in vitro and in situ biomineralization and inducing bone repair. The present invention provides peptides, which are useful in hydrogels and other pharmaceutical compositions, and methods and kits of use for bone repair and promotion of biomineralization. Certain hydrogels according to the invention comprise cells within or adhered to the peptide matrix.

Abstract: Vaccine compositions and methods for protecting a mammalian subject against infection with S. pneumoniae are disclosed. These vaccine compositions include as the active ingredient a purified preparation of the cell wall protein ABC transporter substrate-binding protein having the Accession No. NP_344690 and the amino acid sequence set forth in SEQ ID NO: 32, optionally together with one or more pharmaceutically acceptable adjuvants.

Abstract: The invention provides virus-like particles for treatment of viral infections based on the virus causing the infection. The virus-like particles comprise the virus recombinant proteins that form a capsid, recombinant virus membrane proteins attached to the capsid and vRNA packaged within said capsid. The vRNA is generated from a DNA sequence encoding a polypeptide capable of specifically binding to a constant region of a nonstructural protein of the virus that is essential for propagation of the virus.

Abstract: Vaccine compositions and methods for protecting a mammalian subject against infection with S. pneumoniae are disclosed. These vaccine compositions include as the active ingredient a purified preparation of the cell wall protein NADH oxidase (NOX) having the Accession No. NP_345923 and the amino acid sequence set forth in SEQ ID NO: 8, optionally together with one or more pharmaceutically acceptable adjuvants.

Abstract: The present invention provides a method for producing molybdenum-99 comprising: i) providing an electron accelerator; ii) providing a molybdenum converter/target unit (Mo-CTU) comprising one or more metallic components, wherein each one of said metallic components is made of a material selected from the group consisting of natural molybdenum, molybdenum-100, molybdenum-98, and mixtures thereof; iii) directing an electron beam generated via said electron accelerator onto said Mo-CTU to produce a braking radiation (bremsstrahlung); iv) employing said bremsstrahlung onto said Mo-CTU to produce molybdenum-99 and neutrons via a photo-neutron reaction; v) slowing down the neutrons produced in step iv) with a low atomic liquid, e.g. distilled water; and optionally vi) employing the neutrons produced in step iv) to produce a complementary amount of molybdenum-99 via a neutron capture reaction on said Mo-CTU. The invention further provides an apparatus for producing molybdenum-99.

Abstract: An isolated protein which is at least partially encoded by a polynucleotide sequence encoding a novel acyl-CoA: diacylglycerol acyltransferase 1—like gene (PtDGAT1) from the diatom Phaeodactylum tricomutum is provided together with a composition which includes the isolated protein and a transgenic organism transformed by a polynucleotide encoding same. The invention also provides a method for producing or enhancing the production of oil or triacylglycerols with high saturated fatty acids content.

Abstract: A memory cell with an internal supply feedback loop is provided herein. The memory cell includes a latch having two storage nodes Q and QB, and a supply node. A gating device couples the supply node of the latch to the supply voltage. The gating device is controlled by a feedback loop coming from storage node QB. Due to the aforementioned asymmetric topology, the writing of logic “1” and the writing of logic “0” are carried out differently. Contrary to standard SRAM cells, in the hold states, only the QB storage node presents a valid value of stored data. The feedback loop cuts off the supply voltage for the latch such that the latch is no longer an inverting latch. By cutting off the supply voltage at the stable hold states, while maintaining readability of the memory cell, leakage currents associated with the hold states are eliminated altogether.